

CQ -10-4-1 デクスメデトミジン(DEX)

成人敗血症患者のせん妄予防に、薬物療法を行うか？

検索データベース

■MEDLINE (PubMed/Ovid)

■CENTRAL

■医学中央雑誌

□その他 ()

検索式とヒット数

PubMed search strategy (検索日 2019 年 4 月 22日)

#1	Sepsis[Mesh] OR "Shock, Septic"[Mesh] OR sepsis [tiab] OR (septic[tiab] AND shock[tiab])	175149
#2	("Critical Illness"[Mesh] OR "Critical Care"[Mesh] OR "Intensive Care Units"[Mesh] OR Stressed[tiab] OR "Critically ill"[tiab] OR "Critical care"[tiab] OR "Intensive care"[tiab])	262191
#3	(Delirium[Mesh] OR Delirium[tiab] OR "Consciousness Disorders"[Mesh] OR "Consciousness Disorders"[tiab] OR "Cognitive Dysfunction"[Mesh] OR "Cognitive Dysfunction"[tiab] OR "Sepsis-Associated Encephalopathy"[mesh] OR "Sepsis-Associated Encephalopathy"[tiab] OR "Cognitive impairment"[tiab])	119545
#4	("Drug therapy"[Mesh] OR "Therapeutic Uses"[Mesh] OR Drug[tiab] OR "Central Nervous System Agents"[Mesh] OR "Psychotropic Drugs"[Mesh] OR "Tranquilizing Agents"[Mesh] OR Tranquilize[tiab] OR "Antipsychotic agents"[Mesh] OR Antipsychotic[tiab] OR Haloperidol[Mesh] OR Haloperidol[tiab] OR "Quetiapine Fumarate"[Mesh] OR Quetiapine[tiab] OR Ziprasidone[tiab] OR "Rosuvastatin Calcium"[Mesh] OR Rosuvastatin[tiab] OR Simvastatin[Mesh] OR Simvastatin[tiab] OR Dexmedetomidine[Mesh] OR Dexmedetomidine[tiab])	3715045
#5	(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals [mh] NOT humans [mh]))	3884269
#6	(#1 OR #2) AND #3 AND #4 AND #5	767

CENTRAL search strategy (検索日 2019 年 4 月 24 日)

#1	MeSH descriptor: [Sepsis] explode all trees	3998
#2	(Sepsis):ti,ab,kw	10248
#3	MeSH descriptor: [Shock, Septic] explode all trees	771
#4	(Septic):ti,ab,kw	4108
#5	(Septic Shock):ti,ab,kw	2738
#6	MeSH descriptor: [Critical Illness] explode all trees	1845
#7	MeSH descriptor: [Intensive Care Units] explode all trees	3260
#8	MeSH descriptor: [Critical Care] explode all trees	1918
#9	(Stressed):ti,ab,kw	958
#10	(Critically ill):ti,ab,kw	5980
#11	(Critical care):ti,ab,kw	8789
#12	(Intensive care):ti,ab,kw	25082
#13	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12	43820
#14	MeSH descriptor: [Delirium] explode all trees	551
#15	(Delirium):ti,ab,kw	2824
#16	MeSH descriptor: [Consciousness Disorders] explode all trees	854
#17	(Consciousness Disorder?):ti,ab,kw	855
#18	MeSH descriptor: [Cognitive Dysfunction] explode all trees	837
#19	(Cognitive Dysfunction):ti,ab,kw	5020
#20	MeSH descriptor: [Sepsis-Associated Encephalopathy] explode all trees	0
#21	(Sepsis-Associated Encephalopathy):ti,ab,kw	5
#22	#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21	8237
#23	MeSH descriptor: [Drug Therapy] explode all trees	134017
#24	MeSH descriptor: [Therapeutic Uses] explode all trees	157248
#25	(Drug?):ti,ab,kw	562756
#26	MeSH descriptor: [Central Nervous System Agents] explode all trees	50088
#27	MeSH descriptor: [Psychotropic Drugs] explode all trees	12945
#28	MeSH descriptor: [Tranquilizing Agents] explode all trees	7216
#29	(Tranquiliz*):ti,ab,kw	1220


#30	MeSH descriptor: [Antipsychotic Agents] explode all trees	4354
#31	(Antipsychotic*):ti,ab,kw	9321
#32	MeSH descriptor: [Haloperidol] explode all trees	1343
#33	(Haloperidol):ti,ab,kw	3246
#34	MeSH descriptor: [Quetiapine Fumarate] explode all trees	618
#35	(Quetiapine):ti,ab,kw	1824
#36	(Ziprasidone):ti,ab,kw	774
#37	MeSH descriptor: [Rosuvastatin Calcium] explode all trees	924
#38	(Rosuvastatin):ti,ab,kw	2197
#39	MeSH descriptor: [Simvastatin] explode all trees	1627
#40	(Simvastatin):ti,ab,kw	3605
#41	MeSH descriptor: [Dexmedetomidine] explode all trees	1314
#42	(Dexmedetomidine):ti,ab,kw	3772
#43	#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42	606899
#44	#13 AND #22 AND #43	535
	Trials	524

医学中央雑誌 search strategy (検索日 2019 年 4 月 22 日)

#1	(敗血症/TH or 敗血症/TA) and (PT=会議録除く)	22405
#2	(ショック-敗血症性/TH or 敗血症性/TA or ショック/TA) and (PT=会議録除く)	24933
#3	(危篤/TH or 危篤/TA) and (PT=会議録除く)	150
#4	(クリティカルケア/TH or クリティカルケア/TA or 集中治療/TA) and (PT=会議録除く)	12975
#5	(ICU/TH or ICU/TA) and (PT=会議録除く)	45475
#6	#1 or #2 or #3 or #4 or #5	90181
#7	(せん妄/TH or せん妄/TA) and (PT=会議録除く)	8252
#8	(意識障害/TH or 意識障害/TA) and (PT=会議録除く)	30907
#9	(認知機能低下/TH or 認知機能低下/TA) and (PT=会議録除く)	4039
#10	(敗血症関連脳症/TH or 敗血症関連脳症/TA) and (PT=会議録除く)	10
#11	(認知障害/TH or 認知障害/TA or 認知機能障害/TA) and (PT=会議録除く)	13905

#12	#7 or #8 or #9 or #10 or #11	51896
#13	(薬物療法/TH or 薬物/TA) and (PT=会議録除く)	390112
#14	(治療的利用/TH or 治療的利用/TA) and (PT=会議録除く)	740773
#15	(中枢神経系作用剤/TH or 中枢神経系作用/TA) and (PT=会議録除く)	158573
#16	(向精神剤/TH or 向精神/TA) and (PT=会議録除く)	52494
#17	(精神安定剤/TH or 精神安定/TA) and (PT=会議録除く)	35287
#18	(抗不安剤/TH or 抗不安/TA) and (PT=会議録除く)	15126
#19	(Haloperidol/TH or Haloperidol/TA or ハロペリドール/TA) and (PT=会議録除く)	3358
#20	(Quetiapine/TH or Quetiapine/TA or クエチアピン/TA) and (PT=会議録除く)	1607
#21	(Ziprasidone/TH or Ziprasidone/TA or ジプラシドン/TA) and (PT=会議録除く)	72
#22	(Rosuvastatin/TH or Rosuvastatin/TA or ロスバスタチン/TA) and (PT=会議録除く)	518
#23	(Simvastatin/TH or Simvastatin/TA or シンバスタチン/TA) and (PT=会議録除く)	987
#24	(Dexmedetomidine/TH or Dexmedetomidine/TA or デクスメデトミジン/TA) and (PT=会議録除く)	972
#25	#13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24	895495
#26	(ランダム化比較試験/TH or 準ランダム化比較試験/TH or ランダム化/AL or 無作為化/AL or 比較試験/AL or 臨床試験/AL or プラセボ/AL or 対照/AL or コントロール/AL or 臨床研究/AL)	301704
#27	#6 and #12 and #25 and #26	87


PRISMA フロー図



Risk of Bias サマリー

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abdelgalel 2016	+	?	+	?	+	?	?
Kawazoe 2017	+	+	-	-	+	+	+
Lu 2016	+	?	?	?	?	?	?
Priye 2015	+	?	?	?	?	?	?
Skrobik 2018	+	+	-	+	+	+	+
Su 2016	+	+	+	+	+	+	+
Xuan 2018	+	+	+	+	+	?	?
Zhang 2019	+	+	+	+	+	+	-


Caption
 Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



Caption
 Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

フォレストプロット


アウトカム① 死亡（論文中報告されている最長のもの）



Caption

Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.1 死亡

アウトカム② ICU 退室後の認知機能障害



Caption


Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.2 ICU退室後の認知機能障害（modified Telephone Interview for Cognitive Status: TICS-m）.

Modified TICS 低いほど認知機能障害

術後患者を対象とした研究のみ

アウトカム③ せん妄日数（報告がない薬剤は、せん妄（昏睡） free days）


せん妄日数



Caption
Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.3 せん妄日数

術後患者を対象とした研究はなし


アウトカム④ せん妄発生（04 の報告がない薬剤のみ）



Caption

Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.5 せん妄発生.

アウトカム⑤ 重症な有害事象（致命的イベント、機能不全に関わるもの）




Caption

Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.6 重症な有害事象（機能不全に関わるもの：急性冠症候群、肺炎）.

術後患者を対象とした研究はなし


アウトカム⑥

ICU 滞在期間



Caption
Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.7 ICU滞在期間.


アウトカム⑦ あらゆる軽微な有害事象→未採択（参考値）



Caption
Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.8 徐脈（軽微な有害事象）.

術後患者を対象とした研究はなし

低血圧



Caption

Forest plot of comparison: 1 Dexmedetomidine vs Placebo, outcome: 1.9 低血圧（軽微な有害事象）。

サブグループ解析

術後患者を対象とした研究が含まれていたアウトカムにおいて施行（上記参照）

ファンネルプロット

文献数が 10 以下なので適応外と考えられる